Nayzilam received FDA approval on July 11, 2019 [1].
What is Nayzilam used for?
Nayzilam is approved for the acute treatment of nasal spray seizures, also known as intermittent ictal events or focal seizures, in individuals 8 years of age and older who have been diagnosed with epilepsy [1].
How does Nayzilam work?
Nayzilam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors. By enhancing the effect of GABA, the primary inhibitory neurotransmitter in the brain, Nayzilam increases neuronal inhibition and reduces the excitability of neurons, thereby controlling seizures [1].
When can Nayzilam patents expire?
Information on specific patent expiry dates for Nayzilam is available through resources like DrugPatentWatch.com [2]. Patent protection periods are crucial for determining when generic or biosimilar versions of a drug might become available.
Who manufactures Nayzilam?
Nayzilam is manufactured by UCB Pharma [1].
What are the potential side effects of Nayzilam?
Common side effects associated with Nayzilam include somnolence, dizziness, and nasal discomfort [1]. Due to its sedative effects, patients and caregivers should be aware of the potential for drowsiness, and driving or operating machinery should be avoided after administration until the effects have worn off [1].
What is the difference between Nayzilam and other seizure medications?
Nayzilam is a nasal spray formulation designed for acute treatment of seizures, offering a rapid delivery method that does not require injection. This contrasts with oral medications that may take longer to absorb and with injectable anticonvulsants. The specific type of epilepsy and seizure presentation influences the choice of medication [1].
---
Sources
[1] FDA Approval Letter - Nayzilam (midazolam) nasal spray. (2019, July 11). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211557s000lbl.pdf
[2] DrugPatentWatch.com. (n.d.). https://drugpatentwatch.com/